Cover Image
Market Research Report

Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028

Published by ROOTS ANALYSIS Product code 516633
Published Content info 455 Pages
Delivery time: 1-2 business days
Price
Back to Top
Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
Published: August 17, 2018 Content info: 455 Pages
Description

Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages. It is worth mentioning that the research and development efforts associated with antibody-based therapeutics have significantly paced up in 2017; this momentum is projected to continue over the coming several years. In fact, in 2017, more than 10 monoclonal antibodies were approved by the FDA and EMA. Additionally, close to 20 monoclonal antibodies are currently being evaluated in late stages of clinical development. In addition to monoclonal antibodies, other novel antibody-based therapeutics, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, are steadily gaining traction.

The discovery of antibodies is a long, arduous and cost intensive process. As a result, many biopharmaceutical developers are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery services, claim to have novel and advanced technologies to support players developing antibody-based products in their early stage research requirements. Additionally, there are a number of companies that have developed proprietary antibody discovery platforms and have made them available to drug developers. In-licensing the technology of such players for use in drug discovery operations is considered a viable business strategy, offering both time and cost related benefits to drug / therapy developers. As the demand for such therapeutic / diagnostic products increases, the opportunity for contract service provides and technology developers is also anticipated to grow in the foreseen future.

Synopsis:

The ‘Antibody Discovery: Services and Platforms (2nd Edition), 2018-2028’ report provides an extensive studyon the current market landscape and future outlook of companies offering antibody discovery services and platforms. Amongst various elements, the report includes:

  • A detailed assessment of the current market landscape of companies offering antibody drug discovery services, including information on their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization / and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others).
  • An in-depth analysis of antibody platform providers, featuring information on their geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), type of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others).
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large sized companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • A comparative landscape of service providers, highlighting the most important companies within North America, Europe and Asia Pacific, based on number of discovery services offered, number of discovery methods available, number of subject specific agreements signed, the company's experience and size of employee base.
  • An insightful 2X2 competitiveness analysis of various antibody discovery platforms (segregated into three peer groups, namely library based method, transgenic mice, single cell based method), highlighting popular products based on the library size of the platform, types of antibody discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).
  • Comprehensive profiles of antibody discovery service and platform providers, featuring information on the location of their headquarters, year of establishment, antibody discovery service / platform portfolio, recent developments and a comprehensive future outlook.
  • A case study on antibody humanization and affinity maturation, including an exemplary list of players that are presently offering such services and platforms, a publication analysis highlighting the research trends related to this field and a detailed discussion on other affiliated trends, key drivers and challenges, under a comprehensive SWOT framework.
  • An analysis of the partnerships that have been established in the recent past, covering research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements, merger / acquisitions and othersforms of collaborations.
  • An analysis of investments received by the service and platform providers, featuring details of capital raised via seed financing, venture capital financing, IPOs, debt financing and grants / awards, by companies that are operating within this domain.
  • A discussion on the upcoming opportunities (such as novel antibody therapeutics, innovative technologies and other future opportunities) in the field of drug discovery that are likely to impact the future evolution of this market over the coming years.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. We have provided insights on the likely evolution of the market in different regions, including North America, Europe, China and the rest of the world. In addition, we have provided the likely distribution of the opportunity across the various steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), antibody discovery methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), and the nature of antibody generated (chimeric, humanized and fully human). In addition, we have estimated the future opportunity for platform providers in term of the likely licensing deal structures and the agreements that are expected to be signed in the foreseen future.The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Aaron Sato (Chief Scientific Officer, LakePharma)
  • Christel Iffland (Vice President, Ligand Pharmaceuticals)
  • Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology)
  • Debra Valsamis (Business Development Associate, Antibody Solutions)
  • Garren Hilow (Co-Founder and Chief Executive Officer, Abveris)
  • Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio)
  • Ignacio Pino (President and Chief Executive Officer, CDI Laboratories)
  • Jeng Her (Chief Executive Officer, AP Biosciences)
  • Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera)
  • Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita)
  • Sanjiban K Banerjee (Director, AbGenics Life Sciences)
  • Thomas Schirrmann (Chief Executive Officer and General Manager, YUMAB)

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. During our research, we identified over 70 players that are actively involved in providing antibody discovery services. It is worth highlighting that over 10 companies claim to be capable of offering services across all the steps of the antibody discovery process (antigen designing, hit generation, lead selection and, lead optimization and characterization services). These are (in alphabetical order) Aragen Bioscience, AvantGen, G&P Biosciences, Integral Molecular, IONTAS, LakePharma, WuXi AppTec, Creative BioStructure, Sino Biological, AP Biosciences and ModiQuest Research (acquired by ImmunoPrecise Antibodies).
  • 2. Majority of the companies (39) use library-based methods for antibody discovery. Other methods that are being used include (in decreasing order of number of companies) , hybridoma method (29), transgenic animal-based methods (16) and single cell-based methods (15).
  • 3. Several companies have developed proprietary drug discovery platforms, and are monetizing their efforts by actively out-licensing them to drug developers, CROs and academic institutes. During the course of our study, we identified more than 40 such players. Of these, around 49% are headquartered in North America; examples include (in alphabetical order, no selection criteria) AbCellera, Ablexis, Ligand Pharmaceuticals, Single Cell Technology and TRIANNI. On the other hand, close to 40% of such companies are based in Europe, while the remaining operate out of the Asia Pacific region and rest of the world. Examples of platform providers based in the Europe and Asia Pacific include (in alphabetical order, no selection criteria) AIMM Therapeutics, ACYTE Biotech, BioInvent, Genmab, Harbour BioMed, Heptares Therapeutics, Isogenica, Kymab, Neurimmune and MOLCURE.
  • 4. Over 300 strategic partnerships were forged between drug developers and CROs and / or technology providers during the period 2011-2018. It is worth mentioning that most of these partnerships were research collaborations (31%); this is indicative of the extensive research activity focused on discovering novel antibodies-based product candidates. Technology licensing and product development agreements were the second most popular partnership model, each representing 29% of the total number of deals. Prominent contract services and platform providers that have entered into multiple partnerships include (in alphabetical order) Adimab, Ligand Pharmaceuticals, TRIANNI, Genmab, AbCellera, Crystal Bioscience, MAB Discovery, AbCellera and Isogenica.
  • 5. Over USD 2.6 billion, across 101 funding instances, has been invested in this market. Since 2009, we came across several grants, venture capital funding rounds and public offerings through which capital has been invested in companies in this market. Examples of players that have managed to secure significant capital investments in the period between 2009 and 2018 include (in alphabetical order) argenx, Akeso Biopharma, Kymab, Neurimmune, Sorrento Therapeutics and Zebra Biologics. Further, Bill & Melinda Gates Foundation, OrbiMed Advisors, Google Ventures, Legend Star Capital, Polaris Venture Partners, SV Life Sciences and Wellcome Trust emerged as prominent investors, in terms of their participation in the maximum number of funding instances in the given time period.
  • 6. Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to be worth over USD 2 billion in 2018 and steadily rise in the coming years. With respect to antibody discovery methods, we believe that transgenic animal based method is likely to grow at a faster rate as compared to the established methods such as phage display and hybridoma methods.
  • 7. The major share (over 80%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at faster rate (CAGR of 8.8%) as compared to other regions over the coming decade; this is attributed to the availability of skilled manpower, lower labor costs and a less stringent regulatory environment.
  • 8. The sustained growth is also expected to result in lucrative monetizing opportunities for platform providers as they compete for a share within the USD 3 billion licensing deal revenues over the coming decade (in the form of upfront and milestone payments).

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the antibody discovery services and platforms market and its likely evolution in the mid-long term.

Chapter 3 provides a general overview of antibodies with information on their historical background, structure, isotypes, mechanism of action and applications. It also provides details on the different types of antibodies, namely, monoclonal, bispecific and polyclonal antibodies.

Chapter 4 features information on the antibody discovery process and the various methods used in the discovery of such therapeutic biomolecules. It also includes a comparison of the different antibody discovery methods that are currently available. Additionally, the chapter provides insights on the gradual shift in development trends of monoclonal antibodies over the last three decades, tracking the transition from fully murine to fully human product variants.

Chapter 5 includes a comprehensive market landscape analysis of companies that offer antibody discovery services and / or have proprietary discovery platforms. For antibody discovery service providers, the chapter presents detailed analyses on the basis of their geographical location, types of services offered (antigen designing, hit generation, lead selection, and lead optimization and lead characterization), antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), purpose of antibody discovery (therapeutic and diagnostic) and animal models used (rabbits, rats, mouse, llamas, chicken and others). For antibody discovery platform providers, the chapter includes analyses based on geographical location, antibody generation methods (hybridoma based, library based, single cell based, transgenic animal based, wild type animal based and others), types of antibodies discovered (ADCs, antibody fragments, bispecific antibodies, monoclonal antibodies and others), and animal models used (transgenic mice, rabbits, llamas and others). Additionally, it contains a list of companies that have developed proprietary antibody discovery platforms / technologies to cater to their in-house discovery needs.

Chapter 6 presents a benchmark analysis of all the service providers engaged in this domain. It highlights the capabilities of the various companies in terms of their expertise across antibody discovery, enabling players to compare their existing capabilities within and beyond their respective peer groups and to identify opportunities to become more competitive in the industry.

Chapter 7 provides a comparative landscape of the service providers based on various parameters, such as the number of antibody discovery services offered, number of methods used for the discovery of antibodies, number of collaborations established in the recent past specifically focusing on the discovery and generation of antibodies, company size and experience. Based on the aforementioned analysis, the chapter highlights the most active players within North America, Europe and Asia-Pacific, in a 2X2 matrix.

Chapter 8 providesdetailed profiles of some of the important players, based in different geographies,which are actively engaged in providing antibody discovery services to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information (if available) , details on antibody discovery services and novel antibody discovery technology / platforms, and a comprehensive future outlook.

Chapter 9 featuresa comprehensive 2X2 analysis offering a comparative summary of all the technology platforms that we came across during our research. The analysis compares the aforementioned platforms within four groups [A] library-based technologies [B] transgenic mice-based technology platforms, [C] single cell-based technologies and [D] others. The platforms were compared based on the library size of the platform, types of antibodies discovered, need for humanization, platform-specific collaborations established per year, therapeutic areas addressed and supplier power (in terms of experience of the company).

Chapter 10 providesdetailed profiles of some of the important players, based in different geographies, which are actively providing access / licenses to their antibody discovery technology / platform to biopharmaceutical companies. Each company profile includes a brief overview of the company, financial information (if available) , details on antibody discovery technology / platformsand a comprehensive future outlook.

Chapter 11 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including research collaborations, licensing agreements (related to both technology platforms and service providers), product development, service agreements and merger / acquisitions) and the most common forms of deals / agreements that have been established in the period between 2011 to 2018.

Chapter 12 presents details on various investments received by the companies that are engaged in this domain. It also includes a detailed analysis of the funding instances that have taken place in the period January 2009 to May 2018, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 13 presentsa comprehensive market forecast analysis, highlighting the future potential of the antibody discovery services domain till the year 2028. It features the likely distribution of the upcoming opportunity across [A] key geographies, namely North America, Europe (Germany, Switzerland, UK, France, Belgium and the rest of the Europe), Asia Pacific and rest of the world, [B] steps involved in antibody discovery (antigen designing, hit generation, lead selection, lead optimization and lead characterization), [C] antibody discovery methods (phage display, hybridoma, transgenic animal based, yeast display, single cell based and others), and [D] the nature of antibody generated (murine, chimeric, humanized and fully human). In addition, we have provided a view on the likely upfront and milestone payments to be made in the licensing deals signed or planned with the focus on antibody discovery.

Chapter 14 provides detailed profiles on the top five therapeutic antibody products, which have generated the highest sales till 2017. Each profile covers information on the drug overview, historical sales, and discovery process and methods. The chapter provides information on Humira , Rituxan®, Herceptin®, Remicade®and Avastin®.

Chapter 15 features a case study on antibody humanization and affinity maturation, highlighting the importance of these methods in the process of antibody discovery and development. The chapter presents an exemplary list of key players along with information on location of these companies, their expertise across antibody humanization and / or affinity maturation, the methodology adopted for providing such services and the revenue / business models used by the players involved in this domain. In addition, chapter presents a publication analysis representing the recent trends in research on antibody humanization across various academic institutes, highlighting the ongoing innovation in this domain. Further, the report features a detailed SWOT analysis, which elaborates on the various drivers and challenges that are likely to influence the activities of players engaged in this domain.

Chapter 16 provides an overview of future growth opportunities associated with the field of antibody discovery. The chapter discusses the upcoming antibody therapeutics and technologies, which are being developed / adopted by the antibody drug discovery service and platform providers that are likely to have a notable influence on the industry's evolution over the coming decade.

Chapter 17 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in development of therapeutics for Parkinson's disease. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 18 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (in alphabetical order of person name) Aaron Sato (Chief Scientific Officer, LakePharma), Christel Iffland (Vice President, Ligand Pharmaceuticals), Chun-Nan Chen (Chief Executive Officer and Chief Scientific Officer, Single Cell Technology), Debra Valsamis (Business Development Associate, Antibody Solutions), Garren Hilow (Co-Founder and Chief Executive Officer, Abveris), Giles Day (Co-Founder and Chief Executive Officer, Distributed Bio), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences), Kevin Heyries (Co-Founder and Lead of Business Development Strategy, AbCellera), Nalini Ghag- Motwani (President and Founding Chief Scientist, BioSavita), Sanjiban K Banerjee (Director, AbGenics Life Sciences), , and Thomas Schirrmann (CEO and General Manager, YUMAB).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents
Product Code: RA100115

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Structure of Antibodies
  • 3.3. History of Antibody Discovery
  • 3.4. Antibody Isotypes
  • 3.5. Mechanism of Action of Antibodies
  • 3.6. Classification of Antibodies
    • 3.6.1. Monoclonal Antibodies
    • 3.6.2. Bispecific Antibodies
    • 3.6.3. Polyclonal Antibodies
  • 3.7. Applications of Antibodies

4. ANTIBODY DISCOVERY PROCESS AND METHODS

  • 4.1. Chapter Overview
  • 4.2. Antibody Discovery Process
    • 4.2.1. Target Selection and Validation
    • 4.2.2. Hit Generation
    • 4.2.3. Lead Selection
    • 4.2.4. Lead Optimization
      • 4.2.4.1. Humanization
      • 4.2.4.2. Affinity Maturation
      • 4.2.4.3. Fc Engineering
    • 4.2.5. Lead Characterization
    • 4.2.6. Candidate Selection
  • 4.3. Antibody Discovery Methods
    • 4.3.1. Hybridoma Method
    • 4.3.2. In Vitro Display Methods
      • 4.3.2.1. Phage Display Method
      • 4.3.2.2. Yeast Display Method
      • 4.3.2.3. Ribosomal Display Method
    • 4.3.3. Transgenic Animals Based Method
    • 4.3.4. Single B Cell Based Method
  • 4.4. Advantages and Disadvantages of Antibody Discovery Methods
  • 4.5. Evolution of Monoclonal Antibodies
    • 4.5.1. Fully Human Monoclonal Antibodies

5. COMPETITIVE LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Antibody Discovery Service Providers: Overall Market Landscape
    • 5.2.1. Analysis by Antibody Discovery Steps
    • 5.2.2. Analysis by Antibody Discovery Methods
    • 5.2.3. Analysis by Purpose of Antibody Discovery
    • 5.2.4. Analysis by Type of Antibodies Discovered
    • 5.2.5. Analysis by Animal Model Used
  • 5.3. Antibody Discovery Platform Providers: Overall Market Landscape
    • 5.3.1. Analysis by Antibody Discovery Methods
    • 5.3.2. Analysis by Type of Antibodies Discovered
    • 5.3.3. Analysis by Animal Model Used
    • 5.3.4. Antibody Discovery Service and Platform Providers: Analysis by Geographical Location
  • 5.4. Antibody Discovery Platform Providers: for In-house Purposes

6. BENCHMARK ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Benchmark Analysis: Methodology
  • 6.3. Benchmark Analysis: Peer Groups
  • 6.4. Benchmark Analysis: North America Based Companies
    • 6.4.1. Peer Group I
    • 6.4.2. Peer Group II
    • 6.4.3. Peer Group III
  • 6.5. Benchmark Analysis: Europe and Asia Pacific Based Companies
    • 6.5.1. Peer Group IV
    • 6.5.2. Peer Group V
    • 6.5.3. Peer Group VI

7. COMPARATIVE ANALYSIS OF SERVICE PROVIDERS

  • 7.1. Chapter Overview
  • 7.2. Antibody Discovery Service Providers: Competitive Landscape
  • 7.3. Antibody Discovery Service Providers: Comparative Analysis by Region
    • 7.3.1. Key Players in North America
    • 7.3.2. Key Players in Europe
    • 7.3.3. Key Players in Asia Pacific

8. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS

  • 8.1. Chapter Overview
  • 8.2. Antibody Discovery Service Providers in North America
    • 8.2.1. Abwiz Bio
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Information
      • 8.2.1.3. Antibody Discovery Services
      • 8.2.1.4. Antibody Discovery Platforms
        • 8.2.1.4.1. Needle-in-a-Haystack Technology™
        • 8.2.1.4.2. RabWiz™
        • 8.2.1.4.3. WizAmp™
      • 8.2.1.5. Recent Developments
        • 8.2.1.5.1. Partnerships
        • 8.2.1.6. Future Outlook
    • 8.2.2. Aragen Bioscience (A GVK BIO Company)
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Antibody Discovery Services
      • 8.2.2.3. Recent Developments
        • 8.2.2.3.1. Expansions
        • 8.2.2.3.2. Partnerships
      • 8.2.2.4. Future Outlook
    • 8.2.3. Integral Molecular
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Information
      • 8.2.3.3. Antibody Discovery Services
      • 8.2.3.4. Recent Developments
      • 8.2.3.5. Future Outlook
    • 8.2.4. LakePharma
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Antibody Discovery Services
      • 8.2.4.3. Recent Developments
        • 8.2.4.3.1. Expansions
        • 8.2.4.3.2. Partnerships
      • 8.2.4.4. Future Outlook
  • 8.3. Antibody Discovery Service Providers in Europe
    • 8.3.1. Abzena
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Information
      • 8.3.1.3. Antibody Discovery Services
      • 8.3.1.4. Recent Developments
        • 8.3.1.4.1. Expansions
        • 8.3.1.4.2. Partnerships
      • 8.3.1.5. Future Outlook
    • 8.3.2. MAB Discovery
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Information
      • 8.3.2.3. Antibody Discovery Services
      • 8.3.2.4. Recent Developments
      • 8.3.2.5. Future Outlook
    • 8.3.3. ModiQuest Research (Acquired by ImmunoPrecise Antibodies)
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Antibody Discovery Services
      • 8.3.3.3. Antibody Discovery Platforms
        • 8.3.3.3.1. ModiVacc™
        • 8.3.3.3.2. ModiFuse™: Proprietary Hybridoma Platform
        • 8.3.3.3.3. ModiSelect™: Proprietary B Cell Selection Platform
        • 8.3.3.3.4. ModiPhage™: In-House and Custom Phage Libraries
        • 8.3.3.3.5. ModiTune™: Antibody Optimization Platform
        • 8.3.3.3.6. ModiXpress™: Proprietary In-House Expression Platform
      • 8.3.3.4. Recent Developments
        • 8.3.3.4.1. Partnerships
      • 8.3.3.5. Future Outlook
    • 8.3.4. PX'Therapeutics (Acquired by Aguettant Pharmaceutical Group)
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Antibody Discovery Services
      • 8.3.4.3. Recent Developments
        • 8.3.4.3.1. Partnerships
      • 8.3.4.4. Future Outlook
  • 8.4. Antibody Discovery Service Providers in Asia-Pacific
    • 8.4.1. ChemPartner
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Antibody Discovery Services
      • 8.4.1.3. Recent Developments
        • 8.4.1.3.1. Expansions
        • 8.4.1.3.2. Partnerships
      • 8.4.1.4. Future Outlook
    • 8.4.2. Viva Biotech
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Antibody Discovery Services
      • 8.4.2.3. Recent Developments
        • 8.4.2.3.1. Partnerships
      • 8.4.2.4. Future Outlook
    • 8.4.3. WuXi AppTec
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Financial Information
      • 8.4.3.3. Antibody Discovery Services
      • 8.4.3.4. Recent Developments
        • 8.4.3.4.1. Expansions
        • 8.4.3.4.2. Partnerships
      • 8.4.3.5. Future Outlook

9. COMPETITIVENESS ANALYSIS OF ANTIBODY DISCOVERY PLATFORMS

  • 9.1. Chapter Overview
  • 9.2. Library Based Antibody Discovery Platforms
  • 9.3. Transgenic Animal Based Antibody Discovery Platforms
  • 9.4. Single Cell Based Antibody Discovery Platforms
  • 9.5. Other Antibody Discovery Platforms

10. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS

  • 10.1. Chapter Overview
  • 10.2. Antibody Discovery Platform Providers in North America
    • 10.2.1. Distributed Bio
      • 10.2.1.1. Company Overview
      • 10.2.1.2. Financial Information
      • 10.2.1.3. Antibody Discovery Platforms
        • 10.2.1.3.1. SuperHuman Platform
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Future Outlook
    • 10.2.2. Invenra
      • 10.2.2.1. Company Overview
      • 10.2.2.2. Financial Information
      • 10.2.2.3. Antibody Discovery Platforms
        • 10.2.2.3.1. B-Body™ Platform
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Future Outlook
    • 10.2.3. Ligand Pharmaceuticals
      • 10.2.3.1. Company Overview
      • 10.2.3.2. Financial Information
      • 10.2.3.3. Antibody Discovery Platforms
        • 10.2.3.3.1. OmniAb®
      • 10.2.3.4. Patent Portfolio
      • 10.2.3.5. Recent Developments
      • 10.2.3.6. Future Outlook
    • 10.2.4. Sorrento Pharmaceuticals
      • 10.2.4.1. Company Overview
      • 10.2.4.2. Financial Information
      • 10.2.4.3. Antibody Discovery Platforms
        • 10.2.4.3.1. G-MAB™ Technology
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Future Outlook
    • 10.2.5. TRIANNI
      • 10.2.5.1. Company Overview
      • 10.2.5.2. The Trianni Mouse™ Platform
      • 10.2.5.3. Patent Portfolio
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Future Outlook
    • 10.2.6 Single Cell Technology
      • 10.2.6.1. Company Overview
      • 10.2.6.2. Financial Information
      • 10.2.6.3. Antibody Discovery Platforms
        • 10.2.6.3.1. AbTHENEUM™
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Future Outlook
  • 10.3. Antibody Discovery Platform Providers in Europe
    • 10.3.1. AIMM Therapeutics
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Information
      • 10.3.1.3. Antibody Discovery Platforms
        • 10.3.1.3.1. AIMSelect Platform
      • 10.3.1.4. Recent Developments
      • 10.3.1.5. Future Outlook
    • 10.3.2. BioInvent
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Information
      • 10.3.2.3. Antibody Discovery Platforms
        • 10.3.2.3.1. n-CoDeR® Antibody Library
      • 10.3.2.4. Recent Developments
      • 10.3.2.5. Future Outlook
    • 10.3.3. Genmab
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Information
      • 10.3.3.3. Antibody Discovery Platforms
        • 10.3.3.3.1. DuoBody® Technology
      • 10.3.3.4. Recent Developments
      • 10.3.3.5. Future Outlook
    • 10.3.4. Kymab
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Information
      • 10.3.4.3. Antibody Discovery Platforms
        • 10.3.4.3.1. Kymouse™ Platform
      • 10.3.4.4. Patent Portfolio
      • 10.3.4.5. Recent Developments
      • 10.3.4.6. Future Outlook
  • 10.4. Antibody Discovery Platform Providers in Asia-Pacific
    • 10.4.1. Harbour BioMed
      • 10.4.1.1. Company Overview
      • 10.4.1.2. Financial Information
      • 10.4.1.3. Antibody Discovery Platforms
        • 10.4.1.3.1. H2L2
        • 10.4.1.3.2. HCAb
      • 10.4.1.4. Patent Portfolio
      • 10.4.1.5. Recent Developments
      • 10.4.1.6. Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Antibody Discovery Service and Platform Providers: List of Partnerships and Collaborations
    • 11.3.1. Analysis by Number of Partnerships
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Most Active Players: Analysis by Number of Partnerships
  • 11.4. Concluding Remarks

12. FUNDING AND INVESTMENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Types of Funding
  • 12.3. Antibody Discovery Services and Platforms Market: Funding and Investment Analysis
    • 12.3.1. Analysis by Number of Funding Instances
    • 12.3.2. Analysis by Amount Invested
    • 12.3.3. Analysis by Type of Funding
    • 12.3.4. Analysis by Most Active Players
    • 12.3.5. Analysis by Most Active Investors
  • 12.4. Concluding Remarks

13. OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology
  • 13.3. Antibody Discovery Services Market, 2018-2030 (USD Billion)
  • 13.4. Antibody Discovery Services Market, 2018-2030: Distribution by Geography (USD Billion)
    • 13.4.1. Antibody Discovery Services Market: North America, 2018-2030 (USD Billion)
    • 13.4.2. Antibody Discovery Services Market: Europe, 2018-2030 (USD Billion)
    • 13.4.3. Antibody Discovery Services Market: China, 2018-2030 (USD Billion)
    • 13.4.4. Antibody Discovery Services Market: Rest of the World, 2018-2030 (USD Billion)
    • 13.4.5. Market Attractiveness Analysis by Region
  • 13.5. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps (USD Billion)
  • 13.6. Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods (USD Billion)
    • 13.6.1. Market Attractiveness Analysis by Antibody Discovery Method
  • 13.7. Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated (USD Billion)
  • 13.8. Antibody Discovery Platforms Market, 2018-2030: Licensing Deals (USD Billion)
  • 13.9. Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030

14. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

  • 14.1. Chapter Overview
  • 14.2. Humira® (Adalimumab)
    • 14.2.1. Drug Overview
    • 14.2.2. Discovery Process and Method
    • 14.2.3. Historical Sales
  • 14.3. Rituxan® (Rituximab)
    • 14.3.1. Drug Overview
    • 14.3.2. Discovery Process and Method
    • 14.3.3. Historical Sales
  • 14.4. Herceptin® (Trastuzumab)
    • 14.4.1. Drug Overview
    • 14.4.2. Discovery Process and Method
    • 14.4.3. Historical Sales
  • 14.5. Remicade® (Infliximab)
    • 14.5.1. Drug Overview
    • 14.5.2. Discovery Process and Method
    • 14.5.3. Historical Sales
  • 14.6. Avastin® (Bevacizumab)
    • 14.6.1. Drug Overview
    • 14.6.2. Discovery Process and Method
    • 14.6.3. Historical Sales

15. CASE STUDY: ANTIBODY HUMANIZATION AND AFFINITY MATURATION

  • 15.1. Importance of Antibody Humanization and Affinity Maturation
  • 15.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: Market Landscape
  • 15.3. Antibody Humanization: Publication Analysis
    • 15.3.1. Publication Analysis: Year-Wise Trend
    • 15.3.2. Publication Analysis: Key Journals
    • 15.3.3. Publication Analysis: Distribution by Animal Model Used
    • 15.3.4. Publication Analysis: Distribution by Method Used for Humanization
  • 15.4. Antibody Humanization Service and Platform Providers: SWOT Analysis

16. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

  • 16.1. Chapter Overview
  • 16.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Formats
  • 16.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
  • 16.4. Transition to CADD-based Approaches
  • 16.5. Rising Demand for Antibody-based Treatment Options across Non-Oncology Indications
  • 16.6. Growing Market Opportunities in the Asia-Pacific Region
  • 16.7. Expected Increase in Number of Collaborations and Licensing Activity

17. SURVEY INSIGHTS

  • 17.1. Chapter Overview
  • 17.2. Designation of Respondents
  • 17.3. Antibody Discovery Stages
  • 17.4. Antibody Discovery Methods
  • 17.5. Type of Antibody Discovered
  • 17.6. Location of Antibody Discovery Facility / Laboratory
  • 17.7. Likely Market Size

18. INTERVIEW TRANSCRIPTS

  • 18.1. Chapter Overview
  • 18.2. Aaron Sato, Chief Scientific Officer, LakePharma
  • 18.3. Christel Iffland, Vice President, Ligand Pharmaceuticals
  • 18.4. Chun-Nan Chen, Chief Executive Officer & Chief Scientific Officer, Single Cell Technology
  • 18.5. Debra Valsamis, Business Development Associate, Antibody Solutions
  • 18.6. Garren Hilow, Co-Founder and Chief Executive Officer, Abveris
  • 18.7. Giles Day, Co-Founder and Chief Executive Officer, Distributed Bio
  • 18.8. Ignacio Pino, President and Chief Executive Officer, CDI Laboratories
  • 18.9. Jeng Her, Chief Executive Officer, AP Biosciences
  • 18.10. Kevin Heyries, Co-Founder and Lead of Business Development Strategy, AbCellera
  • 18.11. Nalini Ghag- Motwani, President and Founding Chief Scientist, BioSavita
  • 18.12. Sanjiban K Banerjee, Director, AbGenics Life Sciences
  • 18.13. Thomas Schirrmann, Chief Executive Officer and General Manager, YUMAB

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Basic Structure of an Antibody
  • Figure 3.2: Historical Timeline of Antibody Development
  • Figure 3.3: Mechanism of Action of Antibodies
  • Figure 3.4: Applications of Antibodies
  • Figure 4.1: Overview of the Antibody Discovery Process
  • Figure 4.2: Antibody Discovery Process: Hybridoma Method
  • Figure 4.3: Antibody Discovery Process: Phage Display Method
  • Figure 4.4: Antibody Generation Using Transgenic Animals
  • Figure 4.5: Approved Monoclonal Antibodies: Development Trend Analysis
  • Figure 4.6: Approval Timeline of Fully Human Monoclonal Antibody Therapeutics
  • Figure 4.7: Fully Human Monoclonal Antibodies: Distribution by Discovery Method
  • Figure 5.1: Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
  • Figure 5.2: Antibody Discovery Services Providers: Antibody Discovery Methods
  • Figure 5.3: Antibody Discovery Services Providers: Distribution by Purpose of Antibody Discovery
  • Figure 5.4: Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered
  • Figure 5.5: Antibody Discovery Service Providers: Distribution by Animal Model Used
  • Figure 5.6: Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
  • Figure 5.7: Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered
  • Figure 5.8: Antibody Discovery Platform Providers: Distribution by Animal Model Used
  • Figure 5.9: Antibody Discovery Service and Platform Providers: Geographical Distribution
  • Figure 6.1: Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
  • Figure 6.2: Benchmark Analysis: North America Based Companies, Peer Group I
  • Figure 6.3: Benchmark Analysis: North America Based Companies, Peer Group II
  • Figure 6.4: Benchmark Analysis: North America Based Companies, Peer Group III
  • Figure 6.5: Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group IV
  • Figure 6.6: Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group V
  • Figure 6.7: Benchmark Analysis: Europe and Asia-Pacific Based Companies, Peer Group VI
  • Figure 7.1: Antibody Discovery Service Providers: Competitive Landscape in North America
  • Figure 7.2: Antibody Discovery Service Providers: Competitive Landscape in Europe
  • Figure 7.3: Antibody Discovery Service Providers: Competitive Landscape in Asia-Pacific
  • Figure 8.1: Abwiz Bio: Antibody Discovery Services
  • Figure 8.2: LakePharma: Antibody Discovery Services
  • Figure 8.3: Abzena: Antibody Discovery Services
  • Figure 8.4: ChemPartner: Antibody Discovery Services
  • Figure 9.1: Platform Competitiveness Analysis: Library Based Antibody Discovery Platforms
  • Figure 9.2: Platform Competitiveness Analysis: Transgenic Animal Based Antibody Discovery Platforms
  • Figure 9.3: Platform Competitiveness Analysis: Single Cell Based Antibody Discovery Platforms
  • Figure 9.4: Platform Competitiveness Analysis: Other Platforms
  • Figure 10.1: Ligand Pharmaceuticals: Technology Portfolio
  • Figure 10.2: Ligand Pharmaceuticals: Annual Revenues, 2012- Q1 2018 (USD Million)
  • Figure 10.3: AIMM Therapeutics: Technology Platforms
  • Figure 10.4: Sorrento Therapeutics: Technology Platforms
  • Figure 10.5: Genmab: Technology Platforms
  • Figure 11.1: Distribution by Number of Collaborations
  • Figure 11.2: Distribution by Type of Partnership
  • Figure 11.3: Year-Wise Distribution by Type of Collaboration
  • Figure 11.4: Distribution by Type of Partnership Among Platform and Service Providers
  • Figure 11.5: Leading Players by Number of Partnerships
  • Figure 11.6: Key Focus Areas
  • Figure 11.7: Antibody Discovery Services and Platforms Collaborations: Novel Antibody Types (2017-2018)
  • Figure 12.1: Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018
  • Figure 12.2: Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
  • Figure 12.3: Funding and Investment Analysis: Distribution of Amount Invested by Year, 2009-2018 (USD Million)
  • Figure 12.4: Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
  • Figure 12.5: Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018
  • Figure 12.6: Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
  • Figure 12.7: Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
  • Figure 12.8: Funding and Investment Analysis: Most Active Players
  • Figure 12.9: Funding and Investment Analysis: Most Active Investors
  • Figure 12.10: Funding and Investment Summary
  • Figure 13.1: Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
  • Figure 13.2: Antibody Discovery Services Market, 2018 and 2028: Distribution by Geography, Base Scenario (USD Billion)
  • Figure 13.3: Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
  • Figure 13.4: Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
  • Figure 13.5: Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion)
  • Figure 13.6: Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
  • Figure 13.7: Antibody Discovery Services: Market Attractiveness Analysis by Geography
  • Figure 13.8: Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Base Scenario (USD Billion)
  • Figure 13.9: Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
  • Figure 13.10: Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
  • Figure 13.11: Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
  • Figure 13.12: Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Base Scenario (in Percentage)
  • Figure 13.13: Antibody Discovery Services Market, 2018-2030: Distribution by Type of Antibody Generated, Base Scenario (USD Billion)
  • Figure 13.13: Antibody Discovery Platforms Market, 2018-2030: Number of Licensing Deals 2018 and 2030
  • Figure 13.13: Antibody Discovery Platforms Market, 2018 2030: Upfront and Milestone Payments, 2018, 2025 and 2030
  • Figure 14.1: Humira®: Annual Sales, 2013-2017 (USD Billion)
  • Figure 14.2: Rituxan®: Annual Sales, 2013-2017 (USD Billion)
  • Figure 14.3: Herceptin®: Annual Sales, 2013-2017 (USD Billion)
  • Figure 14.4: Remicade®: Annual Sales, 2013-2017 (USD Billion)
  • Figure 14.5: Avastin®: Annual Sales, 2013-2017 (USD Billion)
  • Figure 14.1: Publication Analysis: Quarterly Distribution
  • Figure 14.2: Publication Analysis: Distribution by Key Journals
  • Figure 14.3: Publication Analysis: Distribution by Study Model
  • Figure 14.4: Publication Analysis: Distribution by Method Used for Humanization
  • Figure 14.6: Antibody Humanization Service and Platform Providers: SWOT Analysis
  • Figure 14.7: Antibody Humanization Service and Platform Providers: Strengths Overview
  • Figure 14.8: Antibody Humanization Service and Platform Providers: Weaknesses Overview
  • Figure 14.9: Antibody Humanization Service and Platform Providers: Opportunities Overview
  • Figure 14.10: Antibody Humanization Service and Platform Providers: Threats Overview
  • Figure 16.1: Future Opportunities Related to Upcoming Trends in Drug Discovery
  • Figure 16.2: Number of Licensing Deals, 2011- 2017
  • Figure 17.1: Survey Insights: Distribution of Respondents by Location of Company Headquarters
  • Figure 17.2: Survey Insights: Distribution by Designation and Seniority Level
  • Figure 17.3: Survey Insights: Distribution by Antibody Discovery Stages
  • Figure 17.4: Survey Insights: Distribution by Antibody Discovery Methods
  • Figure 17.5: Survey Insights: Distribution by Type of Antibody Discovered
  • Figure 17.6: Survey Insights: Distribution by Location of Antibody Discovery Facility / Laboratory
  • Figure 17.7: Survey Insights: Distribution by Likely Market Size

List of Tables:

  • Table 3.1: Antibody Isotypes: Key Features
  • Table 3.2: Mechanism of Action of Therapeutic Antibodies against Different Target Classes
  • Table 3.3: Differences Between Polyclonal and Monoclonal Antibodies
  • Table 4.1: Antibody Discovery Methods: Advantages and Disadvantages
  • Table 4.2: List of Approved Monoclonal Antibodies
  • Table 5.1: List of Antibody Discovery Service Providers
  • Table 5.2: Distribution by Antibody Discovery Steps
  • Table 5.3: Distribution by Antibody Discovery Methods
  • Table 5.4: Distribution by Purpose of Antibody Discovery
  • Table 5.5: Distribution by Type of Antibodies Discovered
  • Table 5.6: Distribution by Animal Model Used
  • Table 5.7: List of Antibody Discovery Platform Providers
  • Table 5.8: Distribution by Antibody Discovery Methods
  • Table 5.9: Distribution by Type of Antibodies Discovered
  • Table 5.10: Distribution by Animal Model Used
  • Table 5.11: Antibody Discovery Platforms used for In-house Purposes
  • Table 6.1: Benchmark Analysis: Peer Groups
  • Table 7.1: Antibody Discovery Service Providers: Qualitative Comparison of Key Parameters
  • Table 8.1: Abwiz Bio: Future Outlook
  • Table 8.3: Aragen Bioscience: Future Outlook
  • Table 8.4: Integral Molecular: Future Outlook
  • Table 8.5: LakePharma: Future Outlook
  • Table 8.6: Abzena: Future Outlook
  • Table 8.7: MAB Discovery: Future Outlook
  • Table 8.8: PX'Therapeutics: Future Outlook
  • Table 8.9: ChemPartner: Future Outlook
  • Table 8.10: Viva Biotech: Future Outlook
  • Table 8.11: WuXi AppTec: Future Outlook
  • Table 10.1: Antibody Discovery Platform Providers: List of Companies Profiled
  • Table 10.2: Distributed Bio: Future Outlook
  • Table 10.2: Invenra: Future Outlook
  • Table 10.3: OmniAb® Technology: Key Features
  • Table 10.4: OmniAb® Technology: Patent Information
  • Table 10.5: OmniChicken® Technology: Patent Information
  • Table 10.6: Ligand Pharmaceuticals: Future Outlook
  • Table 10.7: Sorrento Therapeutics: Future Outlook
  • Table 10.8: The Trianni Mouse™: Key Features
  • Table 10.9: TRIANNI: Future Outlook
  • Table 10.10: Single Cell Technology: Future Outlook
  • Table 10.11: AIMSelect Platform: Key Features
  • Table 10.12: AIMM Therapeutics: Future Outlook
  • Table 10.13: BioInvent: Future Outlook
  • Table 10.14: Kymab: Funding Instances
  • Table 10.15: Kymouse™: Key Features
  • Table 10.16: Kymab: Future Outlook
  • Table 10.17: H2L2 Platform: Key Features
  • Table 10.18: HCAb Platform: Key Features
  • Table 10.19: Harbour BioMed: Future Outlook
  • Table 11.1: Antibody Discovery Services and Platforms: Partnerships and Collaborations, 2011-2018
  • Table 12.1: Antibody Discovery Service and Platform Providers Market: Funding and Investments, 2009-2018
  • Table 12.2: Funding and Investment Analysis: Summary of Investments
  • Table 14.1: Top Ten Selling Therapeutic Antibodies, 2017
  • Table 14.1: Approved Monoclonal Antibodies: Information on Affinity
  • Table 14.2: Antibody Humanization and Affinity Maturation: Service and Platform Providers
  • Table 14.3: Antibody Humanization and Affinity Maturation: Description of Services and Platform Providers
  • Table 14.4: Antibody Humanization: Recent Publications
  • Table 14.5: Antibody Humanization: Modified CDR Grafting Methods
  • Table 16.1: Antibody Discovery Services and Platform Providers: Asia-Pacific Region
  • Table 17.1: Survey Insights: Overview of Respondents
  • Table 17.2: Survey Insights: Designations and Seniority Levels
  • Table 17.3: Survey Insights: Antibody Discovery Stages
  • Table 17.4: Survey Insights: Antibody Discovery Methods
  • Table 17.5: Survey Insights: Type of Antibody Discovered
  • Table 17.6: Survey Insights: Location of Antibody Discovery Facility / Laboratory
  • Table 17.7: Survey Insights: Likely Current Market Size
  • Table 19.1: Approved Monoclonal Antibodies: Development Trend Analysis
  • Table 19.2: Fully Human Monoclonal Antibodies: Distribution by Discovery Method
  • Table 19.3: Antibody Discovery Service Providers: Distribution by Antibody Discovery Steps
  • Table 19.4: Antibody Discovery Service Providers: Distribution by Antibody Discovery Methods
  • Table 19.5: Antibody Discovery Service Providers: Distribution by Purpose of Antibody Discovery
  • Table 19.6: Antibody Discovery Service Providers: Distribution by Type of Antibodies Discovered
  • Table 19.7: Antibody Discovery Service Providers: Distribution by Animal Model Used
  • Table 19.8: Antibody Discovery Platform Providers: Distribution by Antibody Discovery Methods
  • Table 19.9: Antibody Discovery Platform Providers: Distribution by Type of Antibodies Discovered
  • Table 19.10: Antibody Discovery Platform Providers: Distribution by Animal Model Used
  • Table 19.11: Antibody Discovery Service and Platform Providers: Geographical Distribution
  • Table 19.12: Benchmark Analysis: Regional Distribution of Companies by Year of Establishment
  • Table 19.13: Abzena: Annual Revenues, 2013-H1 2018 (EUR Million)
  • Table 19.14: WuXi AppTec: Annual Revenues, 2012-Q1 2018 (USD Million)
  • Table 19.15: Ligand Pharmaceuticals: Annual Revenues, 2012-Q1 2018 (USD Million)
  • Table 19.16: Partnerships and Collaborations: Distribution by Number of Partnerships, 2011-2018
  • Table 19.17: Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2018
  • Table 19.18: Partnerships and Collaborations: Year-Wise Distribution by Type of Collaboration
  • Table 19.19: Partnerships and Collaborations: Distribution by Type of Partnership Among Platform and Service Providers
  • Table 19.20: Partnerships and Collaborations: Leading Players by Number of Partnerships
  • Table 19.21: Partnerships and Collaborations: Distribution by Key Focus Areas
  • Table 19.22: Partnerships and Collaborations: Novel Antibody Types (2017-2018)
  • Table 19.23: Funding and Investment Analysis: Distribution of Number of Funding Instances by Year, 2009-2018
  • Table 19.24: Funding and Investment Analysis: Distribution of Average Funding Amount by Year, 2009-2018 (USD Million)
  • Table 19.25: Funding and Investment Analysis: Distribution of Amount Invested by Year, 2009-2018 (USD Million)
  • Table 19.26: Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
  • Table 19.27: Funding and Investment Analysis: Number of Funding Instances by Type of Funding, 2009-2013 and 2014-2018
  • Table 19.28: Funding and Investment Analysis: Distribution by Type of Funding, 2009-2018
  • Table 19.29: Funding and Investment Analysis: Distribution by Amount of Funding, 2009-2018
  • Table 19.30: Funding and Investment Analysis: Most Active Players
  • Table 19.31: Funding and Investment Analysis: Most Active Investors
  • Table 19.32: Antibody Discovery Services Market, 2018-2030: Conservative Scenario (USD Billion)
  • Table 19.33: Antibody Discovery Services Market, 2018-2030: Base Scenario (USD Billion)
  • Table 19.34: Antibody Discovery Services Market, 2018-2030: Optimistic Scenario (USD Billion)
  • Table 19.35: Antibody Discovery Services Market, 2018 and 2030: Distribution by Region (USD Billion)
  • Table 19.36: Antibody Discovery Services Market, 2018-2030: North America, Conservative Scenario (USD Billion)
  • Table 19.37: Antibody Discovery Services Market, 2018-2030: North America, Base Scenario (USD Billion)
  • Table 19.38: Antibody Discovery Services Market, 2018-2030: North America, Optimistic Scenario (USD Billion)
  • Table 19.39: Antibody Discovery Services Market, 2018-2030: Europe, Conservative Scenario (USD Billion)
  • Table 19.40: Antibody Discovery Services Market, 2018-2030: Europe, Base Scenario (USD Billion)
  • Table 19.41: Antibody Discovery Services Market, 2018-2030: Europe, Optimistic Scenario (USD Billion)
  • Table 19.42: Antibody Discovery Services Market, 2018-2030: China, Conservative Scenario (USD Billion)
  • Table 19.43: Antibody Discovery Services Market, 2018-2030: China, Base Scenario (USD Billion)
  • Table 19.44: Antibody Discovery Services Market, 2018-2030: China, Optimistic Scenario (USD Billion)
  • Table 19.45: Antibody Discovery Services Market, 2018-2030: Rest of the World, Conservative Scenario (USD Billion)
  • Table 19.46: Antibody Discovery Services Market, 2018-2030: Rest of the World, Base Scenario (USD Billion)
  • Table 19.47: Antibody Discovery Services Market, 2018-2030: Rest of the World, Optimistic Scenario (USD Billion)
  • Table 19.48: Antibody Discovery Services: Market Attractiveness Analysis by Region
  • Table 19.49: Antibody Discovery Services Market, 2018-2030: Distribution by Steps Involved in Antibody Discovery Process, Conservative Scenario (USD Billion)
  • Table 19.50: Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Base Scenario (USD Billion)
  • Table 19.51: Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Steps, Optimistic Scenario (USD Billion)
  • Table 19.52: Antibody Discovery Services Market, 2018, 2023, 2030: Distribution by Antibody Discovery Methods (USD Billion)
  • Table 19.53: Antibody Discovery Services Market, 2018-2028: Distribution by Antibody Discovery Methods, Conservative Scenario (USD Billion)
  • Table 19.54: Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Base Scenario (USD Billion)
  • Table 19.55: Antibody Discovery Services Market, 2018-2030: Distribution by Antibody Discovery Methods, Optimistic Scenario (USD Billion)
  • Table 19.56: Antibody Discovery Services: Market Attractiveness Analysis by Antibody Discovery Method
  • Table 19.57: Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated (USD Billion)
  • Table 19.58: Antibody Discovery Services Market, 2018 and 2030: Distribution by Type of Antibody Generated, Conservative Scenario (USD Billion)
  • Table 19.59: Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Base Scenario (USD Billion)
  • Table 19.60: Antibody Discovery Services Market, 2018 and 2030: Distribution by Nature of Antibody Generated, Optimistic Scenario (USD Billion)
  • Table 19.61: Antibody Discovery Platforms Market, 2018 and 2030: Number of Licensing Deals 2018 and 2030 (USD Billion)
  • Table 19.62: Antibody Discovery Platforms Market, 2018-2030: Upfront and Milestone Payments, 2018, 2025 and 2030
  • Table 19.63: Antibody Discovery Platform Providers: Number of Licensing Deals, 2011- 2017
  • Table 19.64: Survey Insights: Distribution of Respondents by Location of Company Headquarters
  • Table 19.65: Survey Insights: Distribution by Designation and Seniority Level
  • Table 19.66: Survey Insights: Distribution by Antibody Discovery Stages
  • Table 19.67: Survey Insights: Distribution by Antibody Discovery Methods
  • Table 19.68: Survey Insights: Distribution by Type Antibody Discovered
  • Table 19.69: Survey Insights: Location of Antibody Discovery Facility / Laboratory
  • Table 19.70: Survey Insights: Likely Current Market Size

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. 4-Antibody
  • 2. A*STAR's Genome Institute of Singapore
  • 3. AB Biosciences
  • 4. Ab Studio
  • 5. ABBA Therapeutics
  • 6. AbBioSci
  • 7. AbbVie
  • 8. AbCellera
  • 9. AbCheck
  • 10. Abeome
  • 11. AbGenics Life Sciences
  • 12. Abgent
  • 13. Ablexis
  • 14. Abpro
  • 15. Absolute Antibody
  • 16. Abwiz Bio
  • 17. Abzena
  • 18. Abzyme Therapeutics
  • 19. Accel
  • 20. Acceleron Pharma
  • 21. Accurus Biosciences
  • 22. Achaogen
  • 23. ACROBiosystems
  • 24. ACYTE Biotech
  • 25. Adagene
  • 26. Adimab
  • 27. Aduro Biotech
  • 28. Advantech Capital
  • 29. Agenus
  • 30. AIMM Therapeutics
  • 31. Aitua
  • 32. Akeagen
  • 33. Alder BioPharmaceuticals
  • 34. Alector
  • 35. Alere
  • 36. Alexandria Real Estate Equities
  • 37. Alexion Pharmaceuticals
  • 38. Ally Bridge Group
  • 39. Amdec Group
  • 40. Amgen
  • 41. Ampersand Capital Partners
  • 42. AnaptysBio
  • 43. AP Biosciences
  • 44. Apexigen
  • 45. Aquila Capital
  • 46. Aragen Bioscience
  • 47. ARCH Venture Partners
  • 48. Argenx
  • 49. Aridis Pharmaceuticals
  • 50. Aristi Biotech
  • 51. Astellas Venture Management
  • 52. AstraZeneca
  • 53. Atlas Venture
  • 54. Atreca
  • 55. AvantGen
  • 56. Avlar BioVentures
  • 57. AxioMx
  • 58. Ballast Point Ventures
  • 59. Bayer
  • 60. BASF
  • 61. BBI Group
  • 62. BeiGene
  • 63. Beijing Shijilongxin Investment
  • 64. Berkeley Lights
  • 65. Bill & Melinda Gates Foundation
  • 66. BioAtla
  • 67. Biogen
  • 68. BioGeneration Ventures
  • 69. BioInvent International
  • 70. BioLauncher
  • 71. Biomirex
  • 72. BioNTech
  • 73. Bio-Rad
  • 74. BioRap Technologies
  • 75. Biosin
  • 76. BIOTEM
  • 77. Birchmere Labs
  • 78. Bird Rock Bio
  • 79. Blue Sky BioServices
  • 80. bluebird bio
  • 81. Boehringer Ingelheim
  • 82. Borealis Ventures
  • 83. Bristol-Myers Squibb
  • 84. Brigham and Women's Hospital
  • 85. Burrage Capital
  • 86. BVF Partners
  • 87. Canaan Partners
  • 88. Cambridge Antibody Technology
  • 89. Capra Science Antibodies
  • 90. Case Western Reserve University School of Medicine
  • 91. Catalent Biologics
  • 92. Celexion
  • 93. Celgene
  • 94. Cellectis
  • 95. Celltrion
  • 96. Centers for Disease Control and Prevention
  • 97. ChemBio Discovery Solutions
  • 98. ChemPartner
  • 99. Chiome Bioscience
  • 100. Chugai Pharmaceutical
  • 101. Chugai Pharmabody Research
  • 102. Cisbio
  • 103. CNA Development
  • 104. Compass Therapeutics
  • 105. Compugen
  • 106. Commission for Technology and Innovation
  • 107. ContraFect
  • 108. Corixa
  • 109. Cormorant Pharmaceuticals
  • 110. Cosmo Pharmaceuticals
  • 111. Creative Biolabs
  • 112. Crescendo Biologics
  • 113. Cresset Biomolecular Discovery
  • 114. Crucell
  • 115. Crystal Bioscience
  • 116. Cullinan Oncology
  • 117. Cytogen
  • 118. DAFNA Capital Management
  • 119. Daiichi Sankyo
  • 120. Dako
  • 121. Dana-Farber Cancer Institute
  • 122. DaTaMabs
  • 123. Defense Threat Reduction Agency
  • 124. Department of Health and Human Services
  • 125. Digital Proteomics
  • 126. Distributed Bio
  • 127. DJS Antibodies
  • 128. Dyax
  • 129. Effimune
  • 130. Elan
  • 131. Eli Lilly
  • 132. Elusys Therapeutics
  • 133. EMBL Ventures
  • 134. Emergent BioSolutions
  • 135. Emory University
  • 136. Enthera
  • 137. Enumeral
  • 138. EpiCypher
  • 139. EpimAb Biotherapeutics
  • 140. Erasmus MC Biomedical Fund
  • 141. Essex Bio-Technology
  • 142. Eureka Therapeutics
  • 143. European Investment Bank
  • 144. EVA Basel
  • 145. Evotec
  • 146. Exiris
  • 147. FairJourney Biologics
  • 148. Ferring Pharmaceuticals
  • 149. Five Prime Therapeutics
  • 150. Flanders Innovation and Entrepreneurship
  • 151. Floodgate Fund
  • 152. Forbion Capital Partners
  • 153. Fred Hutchinson Cancer Research Center
  • 154. Fresenius
  • 155. F-star
  • 156. Fusion Antibodies
  • 157. G&P Biosciences
  • 158. Genedata
  • 159. GeneBeyond
  • 160. GeneFrontier
  • 161. Genentech
  • 162. Genetix
  • 163. Genmab
  • 164. Genor Biopharma
  • 165. GenScript
  • 166. Genzyme
  • 167. Georgia Institute of Technology
  • 168. GigaGen
  • 169. Gilead Sciences
  • 170. GlaxoSmithKline
  • 171. Glenmark Pharmaceuticals
  • 172. GlycoNex
  • 173. Grenoble Hospital
  • 174. GTJA Investment Group
  • 175. GVK Biosciences
  • 176. Harbour BioMed
  • 177. Harpoon Therapeutics
  • 178. HD Biosciences
  • 179. HealthCare Ventures
  • 180. Henlix Biotech
  • 181. Heptares Therapeutics
  • 182. Hercules Capital
  • 183. HitGen
  • 184. HQL Pharmaceuticals
  • 185. Humabs BioMed
  • 186. Human Genome Sciences
  • 187. IBC Generium
  • 188. Ibex Biosciences
  • 189. IGEM Therapeutics
  • 190. Igenica Biotherapeutics
  • 191. ImClone Systems
  • 192. Immune Biosolutions
  • 193. Immunex
  • 194. ImmunoChina Pharmaceuticals
  • 195. Immunologix
  • 196. Immunome
  • 197. Immunomedics
  • 198. Immunomic Therapeutics
  • 199. ImmunoPrecise Antibodies
  • 200. Imperial Innovations
  • 201. In-Cell-Art
  • 202. Innovate UK
  • 203. Innovative Targeting Solutions
  • 204. Innovent Biologics
  • 205. Institut Pasteur
  • 206. Institute for the Promotion of Innovation by Science and Technology
  • 207. Integral Molecular
  • 208. Intrexon
  • 209. Invenra
  • 210. IONTAS
  • 211. Isogenica
  • 212. iTeos Therapeutics
  • 213. Janssen Biotech
  • 214. Jazz Pharmaceuticals
  • 215. Jiangsu Hengrui Medicine
  • 216. Johnson & Johnson
  • 217. Jounce Therapeutics
  • 218. Juno Therapeutics
  • 219. Kaken Pharmaceutical
  • 220. KBC Private Equity
  • 221. KindredBio
  • 222. King Star
  • 223. Kite Pharma
  • 224. Kodiak Sciences
  • 225. Kymab
  • 226. Kyowa Hakko Kirin
  • 227. LakePharma
  • 228. Leland Stanford Junior University
  • 229. LEO Pharma
  • 230. Les Laboratoires Servier
  • 231. Life Sciences Partners
  • 232. Ligand Pharmaceuticals
  • 233. Lilly Asia Ventures
  • 234. LYFE Capital
  • 235. MAB Discovery
  • 236. MabPlex
  • 237. MabSpace Biosciences
  • 238. MabVax Therapeutics
  • 239. MacroGenics
  • 240. Magenta Therapeutics
  • 241. Malin
  • 242. Massachusetts General Hospital
  • 243. MassBiologics
  • 244. Maverick Therapeutics
  • 245. MD Anderson Cancer Center
  • 246. Medarex
  • 247. Medical Research Council
  • 248. MediMabs
  • 249. MedImmune
  • 250. Meditope Biosciences
  • 251. MEMO Therapeutics
  • 252. Memorial Sloan Kettering Cancer Center
  • 253. Merck
  • 254. Mersana Therapeutics
  • 255. Merus
  • 256. MidCap Financial
  • 257. Millennium Pharmaceuticals
  • 258. Mitsubishi Tanabe Pharma
  • 259. ModiQuest Research
  • 260. Molcure
  • 261. Molecular Devices
  • 262. Molecular Templates
  • 263. Moradec
  • 264. MorphoSys
  • 265. MPM Capital
  • 266. MSM Protein Technologies
  • 267. National Institute of Allergy and Infectious Diseases
  • 268. National Institutes of Health
  • 269. NB Health Laboratory
  • 270. NBE Therapeutics
  • 271. NeoClone
  • 272. Nst.Bio Ventures
  • 273. Neurimmune
  • 274. NGM Biopharmaceuticals
  • 275. North Coast Biologics
  • 276. NovaRock Biotherapeutics
  • 277. Novartis
  • 278. Novimmune
  • 279. Novo Nordisk
  • 280. Numab
  • 281. NXT Ventures
  • 282. Oak BioSciences
  • 283. Olympic Protein Technologies
  • 284. Omnes Capital
  • 285. OncoMed Pharmaceuticals
  • 286. Oncobiologics
  • 287. Oncothyreon
  • 288. Ono Pharmaceutical
  • 289. Open Monoclonal Technology
  • 290. OrbiMed Advisors
  • 291. Organon Teknika
  • 292. ORI Healthcare Fund
  • 293. OriMAbs
  • 294. Ossianix
  • 295. Oxford BioTherapeutics
  • 296. Ozyme
  • 297. Palatin Technologies
  • 298. Pfizer
  • 299. PharmAthene
  • 300. Phylogica
  • 301. Pierre Fabre
  • 302. Polaris Partners
  • 303. Porton Pharma Solutions
  • 304. Potenza Therapeutics
  • 305. Prime Value Capital Management
  • 306. ProteoGenix
  • 307. Proxima Ventures
  • 308. Pure Biologics
  • 309. PX'Therapeutics
  • 310. Qianhai Fund of Funds
  • 311. Qiming Venture Partners
  • 312. QoolAbs
  • 313. Quanta BioDesign
  • 314. Queen Mary University of London
  • 315. RayBiotech
  • 316. Redalpine Venture Partners
  • 317. Regeneron Pharmaceuticals
  • 318. Research Corporation Technologies
  • 319. ResearchPoint Global
  • 320. ribOvax Biotechnologies
  • 321. Roche
  • 322. Rx Biosciences
  • 323. SAB Biotherapeutics
  • 324. Sanofi
  • 325. Scripps Research Institute
  • 326. Sea Lane Biotechnologies
  • 327. Seattle Genetics
  • 328. Selexis
  • 329. Sequoia Capital
  • 330. Sevion Therapeutics
  • 331. Shanghai Jianxin Capital
  • 332. ShangPharma Innovation
  • 333. Shenogen Pharma
  • 334. Shenzhen Capital Group
  • 335. Shenzhen Hepalink Pharmaceutical
  • 336. Shenzhen Innovation Investment Group
  • 337. Shenzhen Xinnuo Health Industry Investment
  • 338. Shire
  • 339. Siamab Therapeutics
  • 340. Silicon Valley Bank
  • 341. Silverton Partners
  • 342. Singapore Immunology Network
  • 343. Single Cell Technology
  • 344. Sino Biological
  • 345. Soligenix
  • 346. Sorrento Therapeutics
  • 347. SOTIO
  • 348. Specifica
  • 349. Spectrum Pharmaceuticals
  • 350. Sphere Fluidics
  • 351. Stanford University
  • 352. Sucampo Pharmaceuticals
  • 353. Surface Oncology
  • 354. Sutro Biopharma
  • 355. SV Life Sciences
  • 356. Swedish Orphan Biovitrum
  • 357. Symphogen
  • 358. Synthetic Biologics
  • 359. Synthon Biopharmaceuticals
  • 360. Takeda Pharmaceutical
  • 361. Tanabe Research Laboratories
  • 362. TeneoBio
  • 363. TetraGenetics
  • 364. Teva Pharmaceutical
  • 365. The French National Institute of Health and Medical Research
  • 366. Theraclone Sciences
  • 367. Theranyx
  • 368. Tizona Therapeutics
  • 369. Torch Biosciences
  • 370. Transgene
  • 371. TransGenic
  • 372. Trellis Bioscience
  • 373. TRIANNI
  • 374. Tri-Institutional Therapeutics Discovery Institute
  • 375. TriWise Capital
  • 376. Twist Bioscience
  • 377. U3 Pharma
  • 378. UCB
  • 379. United Therapeutics
  • 380. University of California
  • 381. University of Southampton
  • 382. University of Texas
  • 383. University of Turku
  • 384. Vaccinex
  • 385. Valeant Pharmaceuticals
  • 386. venBio
  • 387. Versant Ventures
  • 388. VI Ventures
  • 389. Viva Biotech
  • 390. Viventia Bio
  • 391. Wellcome Trust Sanger Institute
  • 392. Woodford Investment Management
  • 393. WuXi AppTec
  • 394. Wyeth
  • 395. XBiotech
  • 396. xCella Biosciences
  • 397. XOMA
  • 398. YUMAB
  • 399. YuRoGen Biosystems
  • 400. Zebra Biologics
  • 401. ZENOAQ
  • 402. Zurich Cantonal Bank
  • 403. Zymeworks
Back to Top